Biopharmaceutical scientists work daily to identify and develop potential preventative and therapeutic medicines for some of the most difficult conditions and diseases, with the unified goal of helping people live longer and healthier lives. Rarely have we been more successful at achieving this goal than with the development and global utilization of vaccines
It doesn't take long to understand why biopharmaceutical research companies have conducted more than 800 clinical trials in Montana.
So far this year, according to the Centers for Disease Control and Prevention (CDC), 159 cases of measles have been reported in 16 states – 36 percent of those occurring in children less than five years of age.
Despite some tremendous strides in vaccine development over the years, vaccines remain a major public health challenge for patients and their families throughout the world. This week we released our Medicines in Development: Vaccines report, which shows there are more than 270 vaccines in the pipeline to prevent and/or treat a wide array of diseases, including various forms of cancer and neurological disorders.
Turkey is at the vanguard of a global trend of implementing universal health coverage. Building on that leadership position, Prime Minister Erdoğan has set a goal for Turkey to become a global leader in the delivery of health services over the next decade. A key element of developing the health care market in Turkey is expanding the country’s biopharmaceutical sector.
Today, PhRMA and its 2013 Research & Hope Awards partners are honoring visionaries in the vaccines and immunization field.
To say that vaccines have changed the world for the better is a dramatic understatement. Vaccines have helped us to eradicate smallpox. They’ve helped to dramatically reduce the scourge of polio around the globe. They’ve prevented and controlled once deadly viruses like measles, rubella, influenzas and a host of other infectious and communicable conditions. They are giving us new preventative and therapeutic tools to use in the fight against some cancers and other diseases.
As you may know from a previous Catalyst post, late last month we unveiled a new report on
I recently had the opportunity to speak to Team Hoyt, a father and son team, that have run over 1,000 endurance races together. Team Hoyt has been inducted into the Ironman Hall of fame, honored with a life size bronze statue of their likeness by the start of the Boston marathon, and presented with the Jimmy V perseverance award.
PhRMA has long supported the FDA’s appropriate use of innovative approaches and regulatory flexibility to establish the safety and efficacy of innovative medicines to address unmet medical needs. We strongly supported the passage last year of the Food and Drug Administration Safety and Innovation Act (
Innovative research and development has led to revolutionary medical treatments and practices that have impacted how we think about preventative medicine.
With the start of school and everyone resuming their normal routine, now is the time to schedule your regular doctor’s visit. Given the craziness of summer, health is often an afterthought -- but now is the time to make it a priority.
The 19th round of Trans-Pacific Partnership (TPP) negotiations in Brunei conclude today, and with countries looking to finalize the agreement by the end of this year, there is much to be done in the coming months.
Making a new treatment available to patients takes more than a decade and a billion dollars. Given the time and resources it takes to successfully bring a drug to market, the need for strong intellectual property (IP) protections in the U.S. and abroad has never been more important.
As we’ve previously noted on the Catalyst, medication adherence continues to be a serious challenge with significant consequences to patient health and costs associated with acute care, hospitalizations and surgery. Today, nearly 145 million Americans suffer from chronic disease, but only one-third take their medications as prescribed.
Across the globe, millions of patients are put at risk by counterfeit, substandard or otherwise unsafe medicines.
At a time when there is growing concern about diversity in clinical trials, we learned yesterday that 26 percent of people who participate in treatment trials at the Medical University of South Carolina's Hollings Cancer Center (HCC) are African American.
The PhRMA Foundation is seeking applications for its Young Investigator Center for Adherence Improvement Award. The award will provide stipend support for individuals who are doing research that will advance and improve medication adherence.
Last month, PhRMA and the European Federation of Pharmaceutical Industries and Associations (EFPIA) endorsed joint Principles for Responsible Clinical Trial Data Sharing: Our Commitment to Patients and Researchers.